Figure 4.Survival analysis of AML patients who received intensive chemotherapy or intensive chemotherapy followed by allo-SCT, according to PARP10 expression. Overall survival rate (A) and event-free survival rate (B) of AML patients who received intensive chemotherapy versus intensive chemotherapy followed by allo-SCT in the PARP10 high group. Overall survival rate (C) and event-free survival rate (D) of AML patients who received intensive chemotherapy versus intensive chemotherapy followed by allo-SCT in the PARP10 low group.
